Literature DB >> 7491312

Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs.

D W Whalley1, D J Wendt, A O Grant.   

Abstract

Antiarrhythmic drugs have relative specificity for blocking each of the major classes of ion channels that control the action potential. The kinetics of block is determined by the state of the channel. Those channel states occupied at depolarized potentials generally have greater affinity for the blocking drugs. The kinetics of the drug-channel interaction is important in determining the blocking profile observed clinically. The increased mortality resulting from drug treatment in CAST and several atrial fibrillation trials has resulted in a shift in antiarrhythmic drug development from the Na+ channel blocking (Class I) drugs to the K+ channel blocking (Class III) drugs. While both Classes of drugs have a proarrhythmic potential, this may be less for the Class III agents. Their lack of negative inotropy also make them more attractive. It is important that the potential advantages of these agents be evaluated in controlled clinical trials. In several laboratories, the techniques of molecular biology and biophysics are being combined to determine the block site of available drugs. This information will aid in the future development of agents with greater specificity, and hopefully greater efficacy and safety than those currently in clinical use.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491312     DOI: 10.1111/j.1540-8159.1995.tb06990.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  14 in total

1.  Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable?

Authors:  Emmanuel M Kanoupakis; George E Kochiadakis; Emmanuel G Manios; Nikolaos E Igoumenidis; Hercules E Mavrakis; Panos E Vardas
Journal:  J Interv Card Electrophysiol       Date:  2003-02       Impact factor: 1.900

2.  Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2011-10-17       Impact factor: 4.030

Review 3.  Role of late sodium channel current block in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

4.  How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Atr Fibrillation       Date:  2008

5.  Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves.

Authors:  Serge Sicouri; Leif Carlsson; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2010-04-01       Impact factor: 4.030

6.  Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.

Authors:  Serge Sicouri; Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-01

Review 7.  Atrial-selective sodium channel blockers: do they exist?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2008-08       Impact factor: 3.105

Review 8.  Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.

Authors:  Charles Antzelevitch; Alexander Burashnikov
Journal:  J Electrocardiol       Date:  2009-08-20       Impact factor: 1.438

Review 9.  New pharmacological strategies for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

10.  Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; José M Di Diego; Serge Sicouri; Marcela Ferreiro; Leif Carlsson; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-09-16       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.